Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled induction study of risankizumab in moderate to severe Crohn's disease
MOH_2018-02-07_000646Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in Crohn's disease (6 arms), sponsored by AbbVie Inc. Started Dec 2017; status: completed.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2018-02-07_000646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-07_000646.